Tofacitinib for steroid-resistant heart inflammation from immunotherapy
Treatments studied
Part of Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been treated with immunotherapy (like PD-1 or CTLA-4 inhibitors) for any type of cancer.
- You have heart inflammation (myocarditis) caused by immunotherapy, as diagnosed by your doctor.
- Your heart inflammation has not improved after at least 2 days of high-dose steroids (prednisone 0.5 mg/kg per day or more).
- You have stopped taking immunotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This study tests whether a daily pill (tofacitinib) combined with a short course of steroids can help people with active PMR use less steroids over time. You must have high disease activity and not have taken steroids or biologics in the past two weeks.
This trial tests combining two oral medications, iguratimod and tofacitinib (Xeljanz), to see if they work better together for rheumatoid arthritis that is not well controlled on current treatment.
This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.
Hear when a new Glucocorticoid Resistant ICIs-related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.